Hepatitis C – days of interferon based treatment are gone.
Hepatitis C will be treated by single oral tablet.
Sofosbuvir alone or in combination with ladispavir – A revolution
in the treatment of Hepatitis C
New England journal of medicine published 3-research article
in april – may 2014.
Shows result of fixed dose combinations of two drugs (fixed
dose combination means they will be available as single tablets)
(See my previous blog
in Hepatitis C for current recommendation with sofosbuvir)
In this post I will be posting about fix dose combination of
Sofosbuvir with Ledispavir which got FDA approval recently.
1.
Previously Treated but failed with interferon.
·
In patients without cirrhosis this new drug
combination gave Sustained Virological response (see my previous blog) in 95%
of patient with 12 week therapy and 99% in 24 week therapy
·
With cirrhosis It gave response rates of 86% at
12 week and 99% at 24 week.
·
If we add ribavirin (another drug see my
previous posts), It gave response rates of almost 100% without cirrhosis at 12
and 24 week without cirrhosis
·
With cirrhosis if we add ribavirin than response
rates were 82% at 12 weeks and 99% at 24 weeks.
2.
Long term Hepatitis without Cirrhosis.
·
94% sustained virological response at 8 weeks and
95% at 12 weeks without ribavirin
·
93% with ribavirin at 8 weeks and 97.5 % at 12
weeks.
3.
Untreated Hepatitis C
·
95% Sustained virological response at 12 week
and 98% at 24 week in sofosbuvir-ladispavir
fixed dose combination (single tablet).
·
97% at 12 week with ribavirin and 99% at 24
week.
Ø
TAKE HOME POINTS:
·
NEED OF INTERFERON WILL BE LESS AND LESS AFTER
THIS DRUG AND SO WE WILL BE ABLE TO AVOID ITS TOXICITY
·
EXCELLENT RESULT IN PATIENT OF CIRRHOSIS. THIS
GROUP IS LIKELY TO BENEFIT THE MOST.
·
SINGLE TABLET SO TREATMENT WILL BE EASY FOR
PATIENT
·
MAY BE HELPFUL IN POST TRANSPLANT PATIENTS TO
AVOID RECURRENCE. (TRIALS ARE GOING ON)
·
COST NEED TO BE DECREASED.
No comments:
Post a Comment